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Background
Studies in developed countries have shown that drug
interactions (DI) involving antiretroviral therapy (ARV)
are frequent and under-recognized. No similar work has
been carried out in developing countries, where use of
fixed dose combinations (FDCs) limits the scope for dose
modification.
Methods
Retrospective survey of a large database of HIV+ adults
enrolled into Ampath programme. Details of age, gender,
weight, ARVs and concomitant medications were
recorded. DI were identified from http://www.hiv-drugin
teractions.org and classified as: major (potential to cause
life-threatening illness or hospitalization, 'contra-indi-
cated' or 'not recommended' in SPC, or requiring dose
modification of either, or both drugs); moderate (recom-
mendation to 'avoid' in SPC, or having a >50% effect on
the AUC); minor (likelihood of interaction [actual or the-
oretical] or having an effect of 25–50% AUC).
Summary of results
Data from 1,000 consecutive patients (363 male, 637
female, aged 13 – 68 years; mean body weight 61.3 kg),
who were followed up for 1–21 months (median 9, total
8,594 patient-months of follow up) were included. 750
(75%) were on first-line ARV (d4T, 3TC, NVP) and the use
of individual drugs was as follows: d4T 758(75.8%), 3TC
950(95%), ZDV 211(21.2%), NVP 613 (61.3%), EFV 264
(26.4%), and LPVr 55 (5.5%). All ARVs were prescribed at
standard doses, regardless of whether a DI was present or
not. Major interactions were identified in 187 patients
(18.7%), predominantly involving rifampicin 104
(10.4%) and azoles 82 (8.2%). Moderate interactions
were identified in 142 patients (14.2%), involving ster-
oids 76 (7.6%), azoles 34 (3.4%) and antimalarials 27
(2.7%) patients. Minor interactions were recorded for 44
patients (4.4%). A total of 279 patients (27.9%) had
either a major or moderate interaction, while no drug
interactions were recorded in 698 patients (69.8%).
Conclusion
Clinically significant DIs were common, affecting over 1/
4 patients receiving ART in Kenya, yet are frequently not
recognized. Although TB medications accounted for a sig-
nificant proportion of DIs, we identified other important
interactions involving ARVs and azoles, as well as antima-
larials. Given the relative lack of laboratory monitoring
and widespread use of FDCs, strategies need to be devel-
oped urgently to avoid important drug interactions, to
identify early markers of toxicity, and to manage unavoid-
able interactions safely, in order to reduce risk of harm,
and to maximize the effectiveness of mass ARV deploy-
ment in Africa.
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